CD274 and gastric cancer: A phase III clinical trial (COMPASSION-15 study) showed that the combination of cadonilimab (anti-PD-1/CTLA-4 bispecific antibody) and chemotherapy substantially improved OS and progression-free survival (PFS) of GC patients even with low PD-L1 expression (combined positive score (CPS) < 5) (6).